Company last year acquired three companies as it ramps up production capacity
The decision to enter the European market comes at a time when the global pharmaceutical landscape is undergoing changes
With only one manufacturer currently supplying OCVs worldwide, there has been a deficit of approximately 40 million doses annually
Akum's revenue from operations in Q1FY25 came in at Rs 1019.1 crore, a rise of 5.08 per cent Y-o-Y
The ETS market, valued at Rs 50,350 crore in 2023, is projected to reach Rs 1.09 trillion ($13.2 billion) by 2030, according to the Red Herring Prospectus by Eco Mobility, a car rental company
Firm will focus on animal-free protein production
The BMS was developed in collaboration with Log9 Materials and currently boasts 30 per cent localisation
The decision to expand into South India is a strategic move, driven by the region's rapid growth in the sports car segment, with Bangalore alone witnessing a 35 per cent increase
Non-essential services at government & private hospitals disrupted, even private labs keep shutters down
The improvement in adjusted Ebitda was attributed to cost optimisation efforts driven by technology and product enhancements
This drug has shown a 77.20 per cent ulcer closure rate in clinical trials, offering hope for a condition that often leads to severe outcomes like lower limb amputations
Pricing aimed at disrupting market dominated by Royal Enfield
The company further announced plans to incorporate its own cell technology into its vehicles starting from Q1 of FY26
Fischer Medical Ventures is actively looking to expand its portfolio through acquisitions and investments in high-tech medical imaging and technology solutions
The investment will be used to scale production at Kinetic Green's manufacturing facility in Supa, Maharashtra, and to enhance marketing, distribution, and R&D efforts
Mahindra is coming up with Thar Roxx, and plans to reintroduce the iconic BSA Gold Star Bike
Firm's valuation at Rs 40K cr despite tepid response to IPO
Merck Life Science will supply equipment and technologies to Aragen, facilitating a more efficient clinical-to-commercial process timeline
The company claims this test will be priced between Rs 15,000 and 20,000, making it more affordable than the current market options, which range from Rs 30,000 to 40,000
The API business contributed 2 per cent to consolidated revenues, growing 2 per cent Y-o-Y to Rs 141.5 crore